Originally published as JCO Early Release 10.1200/JCO.2008.19.5396 on February 9 2009

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Le Scodan, R. Articles by Labib, A. Search for Related Content PubMed PubMed Citation Articles by Le Scodan, R. Articles by Labib, A. Social Bookmarking                            What's this?

Breast Cancer With Synchronous Metastases: Survival Impact of Exclusive Locoregional Radiotherapy

From the Departments of Radiation Oncology, Medical Statistics, Medical Oncology, and Surgery, Centre René Huguenin, Saint Cloud, France.

Corresponding author: Romuald Le Scodan, MD, Department of Radiation Oncology, Centre René Huguenin, 35 rue Dailly, 92210, Saint Cloud, France; e-mail: lescodan{at}crh1.org.

Purpose Several studies suggest that surgical excision of the primary tumor improves survival among patients with stage IV breast cancer at diagnosis. Exclusive locoregional radiotherapy (LRR) is an alternative form of locoregional treatment (LRT) in this setting. We retrospectively studied the impact of LRT on the survival of breast cancer patients with synchronous metastases.

Patients and Methods Among 18,753 breast cancer patients treated in our institution between 1980 and 2004, 598 patients (3.2%) had synchronous metastasis at diagnosis. Demographic data, tumor characteristics, metastatic sites, and treatments were prospectively recorded. The impact of LRT on overall survival (OS) was evaluated by multivariate analysis including known prognostic factors.

Results Among 581 eligible patients, 320 received LRT (group A), and 261 received no LRT (group B). LRT consisted of exclusive LRR in 249 patients (78%), surgery of the primary tumor with adjuvant LRR in 41 patients (13%), and surgery alone in 30 patients (9%). With a median follow-up time of 39 months, the 3-year OS rates were 43.4% and 26.7% in group A and group B (P =.00002), respectively. The association between LRT and improved survival was particularly marked in women with visceral metastases. LRT was an independent prognostic factor in multivariate analysis (hazard ratio [HR] = 0.70; 95% CI, 0.58 to 0.85; P = .0002). The adjusted HR for late death ( 1 year) was 0.76 (95% CI, 0.61 to 0.96; P = .02).

Conclusion In our experience, LRT, consisting mainly of exclusive LRR, was associated with improved survival in breast cancer patients with synchronous metastases. Exclusive LRR may thus represent an active alternative to surgery.

Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D.-Y. Chang, C.-H. Lin, and Y.-S. Lu Locoregional Therapy Improves Survival for Metastatic Breast Cancer Patients? Benefit Remains Questionable! J. Clin. Oncol., November 1, 2009; 27(31): e179 - e179. [Full Text] [PDF]

				R. Le Scodan, E. Brain, and D. Stevens Reply to D.-Y. Chang et al J. Clin. Oncol., November 1, 2009; 27(31): e180 - e180. [Full Text] [PDF]